MX2008000609A - Compuestos antivirales. - Google Patents
Compuestos antivirales.Info
- Publication number
- MX2008000609A MX2008000609A MX2008000609A MX2008000609A MX2008000609A MX 2008000609 A MX2008000609 A MX 2008000609A MX 2008000609 A MX2008000609 A MX 2008000609A MX 2008000609 A MX2008000609 A MX 2008000609A MX 2008000609 A MX2008000609 A MX 2008000609A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- carbon atoms
- cycloalkyl
- sulfonamide
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69909605P | 2005-07-14 | 2005-07-14 | |
| US70055905P | 2005-07-18 | 2005-07-18 | |
| PCT/US2006/027605 WO2007009109A2 (en) | 2005-07-14 | 2006-07-14 | Antiviral compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008000609A true MX2008000609A (es) | 2008-03-19 |
Family
ID=37387254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008000609A MX2008000609A (es) | 2005-07-14 | 2006-07-14 | Compuestos antivirales. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070072809A1 (enExample) |
| EP (1) | EP1907403B1 (enExample) |
| JP (1) | JP2009501724A (enExample) |
| KR (1) | KR101345008B1 (enExample) |
| CN (1) | CN101243096B (enExample) |
| AR (1) | AR054838A1 (enExample) |
| AU (1) | AU2006267066A1 (enExample) |
| BR (1) | BRPI0613056A2 (enExample) |
| CA (1) | CA2614276A1 (enExample) |
| MX (1) | MX2008000609A (enExample) |
| NZ (1) | NZ564830A (enExample) |
| TW (1) | TWI389908B (enExample) |
| WO (1) | WO2007009109A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| NZ594105A (en) * | 2005-07-25 | 2013-02-22 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CN101415705B (zh) | 2005-10-11 | 2011-10-26 | 因特蒙公司 | 抑制丙型肝炎病毒复制的化合物和方法 |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
| US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR101512477B1 (ko) | 2006-07-13 | 2015-04-15 | 아칠리온 파르마세우티칼스 인코포레이티드 | 바이러스 복제 억제제로서 사용되는 4-아미노-4-옥소부타노일 펩티드 |
| WO2008033389A2 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Macrocyclic hcv inhibitors and their uses |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2010519266A (ja) * | 2007-02-20 | 2010-06-03 | ノバルティス アーゲー | Hcvns3プロテアーゼ阻害剤としての大員環化合物 |
| SG174809A1 (en) * | 2007-05-03 | 2011-10-28 | Intermune Inc | Macrocyclic compounds useful as inhibitors of hepatitis c virus |
| CN101679277A (zh) | 2007-05-10 | 2010-03-24 | 因特蒙公司 | 丙型肝炎病毒复制的新颖肽抑制剂 |
| KR20100038417A (ko) | 2007-06-29 | 2010-04-14 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| EA025794B1 (ru) | 2007-06-29 | 2017-01-30 | Джилид Сайэнс, Инк. | Противовирусные соединения |
| AR067180A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Compuestos antivirales |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| TW200932255A (en) | 2007-12-21 | 2009-08-01 | Avila Therapeutics Inc | HCV protease inhibitors and uses thereof |
| EP2237666A4 (en) | 2007-12-21 | 2012-05-16 | Avila Therapeutics Inc | HCV PROTEASE INHIBITORS AND USES THEREOF |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8309685B2 (en) * | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| WO2009099596A2 (en) | 2008-02-04 | 2009-08-13 | Idenix Pharamaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| JP5490778B2 (ja) | 2008-03-20 | 2014-05-14 | エナンタ ファーマシューティカルズ インコーポレイテッド | C型肝炎ウイルス阻害剤としてのフッ素化大環状化合物 |
| US8048862B2 (en) * | 2008-04-15 | 2011-11-01 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5529120B2 (ja) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルス阻害剤 |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8614180B2 (en) | 2008-12-10 | 2013-12-24 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2009335904A1 (en) * | 2008-12-19 | 2011-08-04 | Gilead Sciences, Inc. | HCV NS3 protease inhibitors |
| US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
| EP2417134B1 (en) | 2009-04-08 | 2017-05-17 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| AR077712A1 (es) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | Inhibidores de serina proteasa macrociclica |
| PH12012500602A1 (en) * | 2009-09-28 | 2017-08-23 | Intermune Inc | Cyclic peptide inhibitors of hepatitis c virus replication |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| AU2010330862B2 (en) | 2009-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
| US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
| EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2012392557B2 (en) | 2012-10-19 | 2017-06-01 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
| EA201591722A1 (ru) | 2013-03-14 | 2016-02-29 | Ачиллион Фармасьютикалз, Инк. | Новые способы получения совапревира |
| BR112015023351A2 (pt) | 2013-03-15 | 2017-07-18 | Achillion Pharmaceuticals Inc | forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio |
| WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
| WO2014145507A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| SI3236972T1 (sl) | 2014-12-26 | 2021-12-31 | Emory University | Protivirusni derivati N4-hidroksicitidina |
| ES2969239T3 (es) | 2016-05-27 | 2024-05-17 | Gilead Sciences Inc | Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos |
| CN111372592A (zh) | 2017-12-07 | 2020-07-03 | 埃默里大学 | N4-羟基胞苷及衍生物和与其相关的抗病毒用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| ATE167679T1 (de) * | 1990-09-14 | 1998-07-15 | Acad Of Science Czech Republic | Wirkstoffvorläufer von phosphonaten |
| EP0994106B1 (en) * | 1996-12-26 | 2004-03-17 | Shionogi & Co., Ltd. | Process for the preparation of carbamoylated imidazole derivatives |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6457524B1 (en) * | 2000-09-15 | 2002-10-01 | Halliburton Energy Services, Inc. | Well cementing compositions and methods |
| ATE327246T1 (de) * | 2000-11-20 | 2006-06-15 | Bristol Myers Squibb Co | Hepatitis c tripeptid inhibitoren |
| KR100567706B1 (ko) * | 2001-01-31 | 2006-04-05 | 워너-램버트 캄파니 엘엘씨 | 알코올의 카르바모일화 방법 |
| CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| EP1505945B1 (en) * | 2002-05-20 | 2008-11-05 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| US6869964B2 (en) * | 2002-05-20 | 2005-03-22 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis C virus inhibitors |
| CN103203010A (zh) | 2003-05-21 | 2013-07-17 | 贝林格尔.英格海姆国际有限公司 | 包含丙型肝炎抑制剂化合物的药物组合物 |
| US7132504B2 (en) * | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7309708B2 (en) * | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7135462B2 (en) * | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2556669C (en) * | 2004-06-28 | 2012-05-01 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| HRP20070043A2 (hr) * | 2004-07-16 | 2007-07-31 | Gilead Sciences | Antivirusna sredstva |
-
2006
- 2006-07-13 TW TW095125697A patent/TWI389908B/zh not_active IP Right Cessation
- 2006-07-14 EP EP06787506.2A patent/EP1907403B1/en not_active Not-in-force
- 2006-07-14 WO PCT/US2006/027605 patent/WO2007009109A2/en not_active Ceased
- 2006-07-14 KR KR1020087003628A patent/KR101345008B1/ko not_active Expired - Fee Related
- 2006-07-14 BR BRPI0613056-9A patent/BRPI0613056A2/pt not_active IP Right Cessation
- 2006-07-14 MX MX2008000609A patent/MX2008000609A/es active IP Right Grant
- 2006-07-14 CN CN2006800298851A patent/CN101243096B/zh not_active Expired - Fee Related
- 2006-07-14 NZ NZ564830A patent/NZ564830A/en not_active IP Right Cessation
- 2006-07-14 CA CA002614276A patent/CA2614276A1/en not_active Abandoned
- 2006-07-14 AR ARP060103034A patent/AR054838A1/es not_active Application Discontinuation
- 2006-07-14 AU AU2006267066A patent/AU2006267066A1/en not_active Abandoned
- 2006-07-14 US US11/487,542 patent/US20070072809A1/en not_active Abandoned
- 2006-07-14 JP JP2008521690A patent/JP2009501724A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20070072809A1 (en) | 2007-03-29 |
| JP2009501724A (ja) | 2009-01-22 |
| AR054838A1 (es) | 2007-07-18 |
| TWI389908B (zh) | 2013-03-21 |
| EP1907403A2 (en) | 2008-04-09 |
| EP1907403B1 (en) | 2013-12-25 |
| NZ564830A (en) | 2010-12-24 |
| AU2006267066A1 (en) | 2007-01-18 |
| KR101345008B1 (ko) | 2013-12-31 |
| CA2614276A1 (en) | 2007-01-18 |
| WO2007009109A3 (en) | 2007-06-07 |
| BRPI0613056A2 (pt) | 2010-12-14 |
| KR20080027947A (ko) | 2008-03-28 |
| TW200738741A (en) | 2007-10-16 |
| WO2007009109A2 (en) | 2007-01-18 |
| CN101243096A (zh) | 2008-08-13 |
| CN101243096B (zh) | 2013-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008000609A (es) | Compuestos antivirales. | |
| AU2005267800B2 (en) | Nucleoside phosphonate conjugates as anti HIV agents | |
| JP5676839B2 (ja) | 抗ウイルス化合物 | |
| AU2006270264A1 (en) | Antiviral compounds | |
| MX2009000236A (es) | Compuestos de fosfinato antivirales. | |
| MXPA06007095A (es) | Conjugados de fosfonato inhibidores de cinasa. | |
| CA2481285A1 (en) | Non nucleoside reverse transcriptase inhibitors | |
| AU2004283710A1 (en) | Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives | |
| AU2005299284A1 (en) | Phosphonate derivatives of mycophenolic acid | |
| ES2369701T3 (es) | Compuestos antivirales. | |
| AU2011218664B2 (en) | Antiviral compounds | |
| AU2005299504A1 (en) | Phosphonate substituted kinase inhibitors | |
| HK1103648B (en) | Phosphonate prodrugs of a 2'-fluoro-2',3'-didehydro-2',3'-dideoxyadenosine analogue as anti-hiv agents | |
| AU2011224011A1 (en) | Phosphonate analogs of HIV inhibitor compounds | |
| HK1103089B (en) | Antiviral compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |